Daily Market Watch

Tripps and Newman -

Don't be "Negative Nancys" now.

I will lay hands upon it and speak in tongues.:p

Tomorrow is another day.

Here is my philosopy -

It is a relatively small stock. A lot of people read this thread and have learned our strategy with GTXO. You know, the strategy of getting it for a dime. So I think a lot of it could be people trying to get it at a really low price and to some degree that has driven it down.

It doesn't trade that fast during the day to get much counter action, but it still traded today 5 to 1 over CTGI. However, with that said, CTGI gained a penny with one hundred and some thousand shares traded.

fjslkds kssdkf fjkssd jfksdf kjfks fkskd ifikek kfeiiek kdkdi ifkekdk

(That was me speaking in tongues with my hands on the monitor)

Just have to wait and see. I read in Market Watch the other day that GTXO is very sound financially and they just bought another company last week called CANS I believe.

So I wouldn't get depressed or all excited yet.

So have faith brothers and sisters, we shall overcome!

yeah im having a hard time not selling it off as im seeing these damn 6 cent bids

Quote:

---

Originally Posted by ray

hey bill take another look at ctic looks like it is on the move good luck

---

Ray -

That CTIC was all over the ball park today and still closed 50+ percent up. I only watched it for a couple of minutes and it looked like ricochet rabbit.

It looked more like a commodity.

Did you buy some of that?

I will look at their chart. Just from what I saw has me wondering if it is one of those one day wonders. It traded millions of shares today. I shut my watchlist down so I don't remember what the exact volume was.

I will look at it though and see what the scoop is.

Good to hear from you.....I thought you were mad at me :)

Quote:

---

Originally Posted by trippingthespeculatingpos

yeah im having a hard time not selling it off is im seeing these damn 6 cents bids

---

Holy shit....I am turning my watchlist back on....be back

I see bids at 9 and it is currently 9.5

actually the bid is at .066 right now. It has been showing up all day off and on.

Quote:

---

Originally Posted by trippingthespeculatingpos

what u guys think about this play http://research.tdameritrade.com/pub...sp?symbol=CTIC

---

Just my thought......I have a Masters Degree in Anatomy and Physiology and these medical / biochemical / and research companies scare the living crap out of me (just my personal thought). Now I think all of this activity is because of the FDA announcement so everybody is jumping on the band wagon. If a guy could think and move fast he could maybe do o.k.

The volume was HUGE on that stock today. I watched the price for a little while and it was bouncing all over the place, but still came out 50+ percent ahead


I am looking at my watchlist chart here right at the moment.......ya, it was a VERY determined stock today..even with the shorters all over it. It is still on a climb at the end of today. When the climb is going to end I don't have an idea.

Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
1:30a ET January 27, 2009 (PR NewsWire)

Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that after communication with the Food and Drug Administration (FDA), CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non-Hodgkin's lymphoma (NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.

"This communication from the FDA is a significant milestone for the Company and for patients with relapsed aggressive NHL as this could be the first drug approved for this unmet medical need," noted James A. Bianco, M.D. Chief Executive Officer of CTI. "With the potential for three drug approvals in 2009 we are on track to meet our objective of cash flow break even in the fourth quarter of this year."

The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). CR/uCR and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.

The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

Quote:

---

Originally Posted by trippingthespeculatingpos

actually the bid is at .066 right now. It has been showing up all day off and on.

---

I wasn't home all day and I believe you. My AH says 9 and last is 9.5

The last trade that I have recorded was at 15:54:39 for 1000 shares.

what are you using? i used command center which is a 3rd party software from ameritrade. it's the most accurate thing ive seen so far.